NCT03016468撤回2 期
A Multicenter, 16-Week, Open-label Study Evaluating the Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Subjects With Pulmonary Arterial Hypertension
United Therapeutics0 个研究点开始时间: 2017年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 主要终点
- Incidence of Adverse Events (AEs) through 16 Weeks
研究概览
简要总结
This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH). The study will include about 30 subjects at approximately 10 clinical trial centers. The treatment phase of the study will last approximately 16 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a diagnosis of symptomatic idiopathic or heritable PAH, PAH associated with connective tissue disease, PAH associated with HIV infection, PAH associated with repaired congenital systemic-to-pulmonary shunt (at least 1 year since repair with respect to the date of providing informed consent), or PAH associated with appetite suppressant or toxin use.
- •The subject must be classified as WHO FC II or III at Baseline.
- •The subject is receiving selexipag for the treatment of WHO Group 1 PAH for a minimum of 90 days from Baseline.
- •Subject is in need of escalation of therapy, as determined by the Investigator.
- •Subject must be receiving a Food and Drug Administration (FDA)-approved PDE5-I or sGC stimulator and/or an ERA and has been at the current stable dose for at least 28 days prior to Baseline.
排除标准
- •The subject is receiving selexipag for any other disease or condition other than the treatment of WHO Group 1 PAH.
- •The subject has a Baseline 6MWD of less than 150 meters.
- •The subject's Baseline 6MWD has decreased more than 40% from the pre-selexipag baseline.
- •The subject has a history of ischemic heart disease (defined as either symptomatic or requiring anti-anginal therapy or experienced a documented myocardial infarction within the previous 6 months of Baseline), or a history of left sided myocardial dysfunction as evidenced by a PAWP greater than 15 mmHg or a left ventricular ejection fraction less than 40%.
- •The subject has previously been treated with any parenteral prostacyclin or oral treprostinil for a period of 90 days or more.
- •The subject has a history of 1 or more of the following signs of relevant lung disease within 180 days before Baseline:
- •Total lung capacity less than 60% of predicted normal.
- •Forced expiratory volume in 1 second is less than 55% of predicted normal.
研究组 & 干预措施
Parenteral Remodulin then Oral Treprostinil
Experimental
干预措施: Parenteral Remodulin (treprostinil) injection (Drug)
Parenteral Remodulin then Oral Treprostinil
Experimental
干预措施: Oral Treprostinil (Drug)
结局指标
主要结局
Incidence of Adverse Events (AEs) through 16 Weeks
时间窗: 16 Weeks
次要结局
- Change in 6-minute Walk Distance (6MWD) from Baseline to Week 16(Baseline and Week 16)
- Change in Borg Dyspnea Score Immediately After 6-minute Walk Test (6MWT) from Baseline to Week 16(Baseline and Week 16)
- Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to Week 16(Baseline and Week 16)
- Change in Pulmonary Arterial Hypertension (PAH) Symptoms Score from Baseline to Week 16(Baseline and Week 16)
- Change in Score on Treatment Satisfaction Questionnaire for Medication (TSQM) from Baseline to Week 16(Baseline and Week 16)
研究者
相似试验
尚未招募
1 期
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45
已完成
4 期
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.HIV InfectionsNCT00326963Hoffmann-La Roche142
招募中
2 期
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMMMultiple Myeloma in RelapseNCT06255847Shanxi Bethune Hospital43
已完成
3 期
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsMild Hereditary Factor VIII Deficiency Disease Without InhibitorModerate Hereditary Factor VIII Deficiency Disease Without InhibitorHemophilia ANCT04158648Hoffmann-La Roche73
已完成
3 期
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia AHemophilia ANCT03815318Sinocelltech Ltd.73